APPILI THERAPEUTICS INC-CL A (APLI.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:APLI - CA03783R1073 - Common Stock
APLI.CA Key Statistics, Chart & Performance
The current stock price of APLI.CA is 0.02 CAD. In the past month the price decreased by -20%. In the past year, price decreased by -42.86%.
APLI.CA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to APLI.CA. When comparing the yearly performance of all stocks, APLI.CA is a bad performer in the overall market: 95.06% of all stocks are doing better.
APLI.CA Financial Highlights
Over the last trailing twelve months APLI.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 30.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -347.87% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
APLI.CA Forecast & Estimates
APLI.CA Ownership
APLI.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.74 | 3.42B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.39B | ||
| CRON.CA | CRONOS GROUP INC | 24 | 1.38B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 6.96 | 862.47M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 578.48M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 571.91M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 525.95M | ||
| TSND.CA | TERRASCEND CORP | N/A | 379.30M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 16.33 | 377.00M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 329.45M | ||
| HITI.CA | HIGH TIDE INC | N/A | 314.10M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 296.87M |
Related stock screener links
About APLI.CA
Company Profile
Appili Therapeutics, Inc. operates as a biopharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. The company is headquartered in Halifax, Nova Scotia. The company went IPO on 2019-06-25. The firm is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.
Company Info
APPILI THERAPEUTICS INC-CL A
#21-1344 Summer Street
Halifax NOVA SCOTIA B3H 0A8 CA
CEO: Armand Balboni
Employees: 7
Phone: 19024424655
APPILI THERAPEUTICS INC-CL A / APLI.CA FAQ
What does APPILI THERAPEUTICS INC-CL A do?
Appili Therapeutics, Inc. operates as a biopharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. The company is headquartered in Halifax, Nova Scotia. The company went IPO on 2019-06-25. The firm is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.
What is the stock price of APPILI THERAPEUTICS INC-CL A today?
The current stock price of APLI.CA is 0.02 CAD. The price decreased by -20% in the last trading session.
Does APLI stock pay dividends?
APLI.CA does not pay a dividend.
What is the ChartMill rating of APPILI THERAPEUTICS INC-CL A stock?
APLI.CA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists APLI stock?
APLI.CA stock is listed on the Toronto Stock Exchange exchange.
What sector and industry does APPILI THERAPEUTICS INC-CL A belong to?
APPILI THERAPEUTICS INC-CL A (APLI.CA) operates in the Health Care sector and the Pharmaceuticals industry.
When does APPILI THERAPEUTICS INC-CL A (APLI.CA) report earnings?
APPILI THERAPEUTICS INC-CL A (APLI.CA) will report earnings on 2026-02-12.